Skip to main content

CONTROL TRADUCCIONAL MEDIADO POR CPEBS EN LA INTERACCION TUMOR-NICHO: UNA PERSPECTIVA MECANISTICA.

PID2020-119533GB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACIO INSTITUT DE RECERCA BIOMEDICA (BARCELONA)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

GATA6 identifies an immune-enriched phenotype linked to favorable outcomes in patients with pancreatic cancer undergoing upfront surgery

  • van Eijck, Casper W. F.
  • Real, Francisco X.
  • Malats i Riera, Núria
  • Vadgama, Disha
  • van den Bosch, Thierry P. P.
  • Doukas, Michail
  • van Eijck, Casper H. J.
  • Mustafa, Dana A. M.
  • Dutch Pancreatic Cancer Group (DPCG)
This study underscores GATA6's role in distinguishing classical and basal-like pancreatic ductal adenocarcinoma (PDAC) phenotypes. Retrospective studies associate GATA6 immunohistochemistry (IHC) expression with survival outcomes, warranting prospective validation. In a prospective treatment-naive cohort of patients with resected PDAC, GATA6 IHC proves a prognostic discriminator, associating high GATA6 expression with extended survival and the classical PDAC phenotype. However, GATA6's prognostic significance is numerically lower after gemcitabine-based neoadjuvant chemoradiotherapy compared to its significance in patients treated with upfront surgery. Furthermore, GATA6 is implicated in immunomodulation, although a comprehensive investigation of its immunological role is lacking. Treatment-naive PDAC tumors with varying GATA6 expression yield distinct immunological landscapes. Tumors highly expressing GATA6 show reduced infiltration of immunosuppressive regulatory T cells and M2 macrophages but increased infiltration of immune-stimulating, antigen-presenting, and activated T cells. Our findings caution against solely relying on GATA6 for molecular subtyping in clinical trials and open avenues for exploring immune-based combination therapies., The laboratory of C.H.J.v.E. receives financial support from the Survival with Pancreatic Cancer Foundation (www.supportcasper.nl) (grant number OVIT17-06). The laboratory of F.X.R. receives financial support from Ministerio de Ciencia, Innovación y Universidades (grant number PID2020-119533GB-I00). The CNIO receives support from the Ministerio de Ciencia, Innovación y Universidades as a Centro de Excelencia Severo Ochoa (grant number SEV-2015-0510).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

NFIC regulates ribosomal biology and ER stress in pancreatic acinar cells and restrains PDAC initiation

  • Cobo, Isidoro
  • Paliwal, Sumit
  • Bodas, Cristina
  • Felipe, Irene
  • Melià-Alomà, Júlia
  • Torres, Ariadna
  • Martínez-Villarreal, Jaime
  • Malumbres, Marina
  • García, Fernando
  • Millán, Irene
  • Del Pozo, Natalia
  • Park, Joo-Cheol
  • MacDonald, Ray J.
  • Muñoz, Javier
  • Méndez, Raúl
  • Real, Francisco X.
Pancreatic acinar cells rely on PTF1 and other transcription factors to deploy their transcriptional program. We identify NFIC as a NR5A2 interactor and regulator of acinar differentiation. NFIC binding sites are enriched in NR5A2 ChIP-Sequencing peaks. Nfic knockout mice have a smaller, histologically normal, pancreas with reduced acinar gene expression. NFIC binds and regulates the promoters of acinar genes and those involved in RNA/protein metabolism, and Nfic knockout pancreata show defective ribosomal RNA maturation. NFIC dampens the endoplasmic reticulum stress program through binding to gene promoters and is required for resolution of Tunicamycin-mediated stress. NFIC is down-regulated during caerulein pancreatitis and is required for recovery after damage. Normal human pancreata with low levels of NFIC transcripts display reduced expression of genes down-regulated in Nfic knockout mice. NFIC expression is down-regulated in mouse and human pancreatic ductal adenocarcinoma. Consistently, Nfic knockout mice develop a higher number of mutant Kras-driven pre-neoplastic lesions., This work was supported, in part, by grants SAF2011-29530, SAF2015-70553-R, RTI2018-101071-B-I00 from Ministerio de Ciencia, Innovación y Universidades (Madrid, Spain) (co-funded by the ERDF-EU) and RTICC from Instituto de Salud Carlos III (RD12/0036/0034) to FXR and grants PID2020-119533GB-I00, from Ministerio de Ciencia, Innovación y Universidades (Madrid, Spain), and GCB15152955MÉND, from the Spanish Association Against Cancer (AECC), to RM. I.C. was recipient of a Beca de Formación del Personal Investigador from Ministerio de Economía y Competitividad (Madrid, Spain). The research leading to these results has received funding from People Programme (Marie Curie Actions) of the European Union’s Seventh Framework Programme (FP7/2007-2013) (REA grant agreement n° 608765”). S.P. was supported by a Juan de la Cierva Programme fellowship from Ministerio de Ciencia, Innovación y Universidades. C.B. is supported by a FPI Fellowship from Ministerio de Ciencia, Innovación y Universidades. I.M. was supported by a Fellowship from Fundació Bancària La Caixa (ID 100010434) (grant number LCF/BQ/ES18/11670009). CNIO is supported by Ministerio de Ciencia, Innovación y Universidades as a Centro de Excelencia Severo Ochoa SEV-2015-0510.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Pathogenic Mis-splicing of CPEB4 in Schizophrenia

  • Ollà, Ivana
  • Pardiñas, Antonio F.
  • Parras, Alberto
  • Hernández, Ivó H.
  • Santos-Galindo, María
  • Picó, Sara
  • Callado, Luis F.
  • Elorza, Ainara
  • Rodríguez-López, Claudia
  • Fernández-Miranda, Gonzalo
  • Belloc, Eulàlia
  • Walters, James T. R.
  • O'Donovan, Michael C.
  • Méndez, Raúl
  • Toma, Claudio
  • Meana, J. Javier
  • Owen, Michael J.
  • Lucas, José J.
Background: Schizophrenia (SCZ) is caused by an interplay of polygenic risk and environmental factors, which may alter regulators of gene expression leading to pathogenic misexpression of SCZ risk genes. The CPEB family of RNA-binding proteins (CPEB1–4) regulates translation of target RNAs (approximately 40% of overall genes). We previously identified CPEB4 as a key dysregulated translational regulator in autism spectrum disorder (ASD) because its neuronal-specific microexon (exon 4) is mis-spliced in ASD brains, causing underexpression of numerous ASD risk genes. The genetic factors and pathogenic mechanisms shared between SCZ and ASD led us to hypothesize CPEB4 mis-splicing in SCZ leading to underexpression of multiple SCZ-related genes. Methods: We performed MAGMA-enrichment analysis on Psychiatric Genomics Consortium genome-wide association study data and analyzed RNA sequencing data from the PsychENCODE Consortium. Reverse transcriptase polymerase chain reaction and Western blot were performed on postmortem brain tissue, and the presence/absence of antipsychotics was assessed through toxicological analysis. Finally, mice with mild overexpression of exon 4–lacking CPEB4 (CPEB4Δ4) were generated and analyzed biochemically and behaviorally. Results: First, we found enrichment of SCZ-associated genes for CPEB4-binder transcripts. We also found decreased usage of CPEB4 microexon in SCZ probands, which was correlated with decreased protein levels of CPEB4-target SCZ-associated genes only in antipsychotic-free individuals. Interestingly, differentially expressed genes fit those reported for SCZ, specifically in the SCZ probands with decreased CPEB4-microexon inclusion. Finally, we demonstrated that mice with mild overexpression of CPEB4Δ4 showed decreased protein levels of CPEB4-target SCZ genes and SCZ-linked behaviors. Conclusions: We identified aberrant CPEB4 splicing and downstream misexpression of SCZ risk genes as a novel etiological mechanism in SCZ., his work was supported by grants to JJL from: Networking Research Center on Neurodegenerative Diseases (CIBERNED) - Health Institute Carlos III (ISCIII) (Collaborative Grant No. PI2018/06-1), Spanish Ministry of Economy and Competitiveness (MINECO) (Grant No. SAF2015-65371-R), Spanish Ministry of Science, Innovation and Universities (MICIU) (Grant No. RTI2018-096322-B-I00) and Spanish Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033/FEDER,UE Grant No. PID2021-123141OB-I00); by grants to RM from MINECO (PID2020-119533GB-I00) and World Cancer Research Fund International (2020_021); by grants to CT: No. PID2020-114996RB-I00 (MCIU/AEI/FEDER,UE) and RyC2018-024106-I; and by grants to JJM and LFC from Basque Government (Grant Nos. IT-1211-19 and 1512-22). Cardiff University’s work was supported by grants to JTRW, MCO, and MJO from Medical Research Council Centre (Grant No. MR/L010305/1), Program (Grant No. MR/P005748/1), and Project (Grant Nos. MR/L011794/1, MC_PC_17212). AFP was supported by an Academy of Medical Sciences “Springboard” award (SBF005∖1083). IO was hired through European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement (Grant No. 766124). The Center for Molecular Biology Severo Ochoa is a Severo Ochoa Center of Excellence (MICIN, Award CEX2021-001154-S)., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2021-001154-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Mis-splicing of a neuronal microexon promotes CPEB4 aggregation in ASD

  • Garcia-Cabau, Carla
  • Bartomeu, Anna
  • Tesei, Giulio
  • Cheung, Kai Chit
  • Pose-Utrilla, Julia
  • Picó, Sara
  • Balaceanu, Andreea
  • Duran-Arqué, Berta
  • Fernández-Alfara, Marcos
  • Martín, Judit
  • De Pace, Cesare
  • Ruiz-Pérez, Lorena
  • García, Jesús
  • Battaglia, Giuseppe
  • Lucas, José J.
  • Hervás, Rubén
  • Lindorff-Larsen, Kresten
  • Méndez, Raúl
  • Salvatella, Xavier
The inclusion of microexons by alternative splicing occurs frequently in neuronal proteins. The roles of these sequences are largely unknown, and changes in their degree of inclusion are associated with neurodevelopmental disorders1. We have previously shown that decreased inclusion of a 24-nucleotide neuron-specific microexon in CPEB4, a RNA-binding protein that regulates translation through cytoplasmic changes in poly(A) tail length, is linked to idiopathic autism spectrum disorder (ASD)2. Why this microexon is required and how small changes in its degree of inclusion have a dominant-negative effect on the expression of ASD-linked genes is unclear. Here we show that neuronal CPEB4 forms condensates that dissolve after depolarization, a transition associated with a switch from translational repression to activation. Heterotypic interactions between the microexon and a cluster of histidine residues prevent the irreversible aggregation of CPEB4 by competing with homotypic interactions between histidine clusters. We conclude that the microexon is required in neuronal CPEB4 to preserve the reversible regulation of CPEB4-mediated gene expression in response to neuronal stimulation., CBMSO is a Severo Ochoa Center of Excellence (MICIN, award CEX2021-001154-S). K.L.-L. acknowledges support from the Novo Nordisk Foundation (PRISM; NNF18OC0033950). K.L.-L. acknowledges access to computational resources from the Danish National Supercomputer for Life Sciences (Computerome). This project has also received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skodowska-Curie grant agreement number 101025063. R.M. was supported by grants from the Spanish Ministry of Science, Innovation and Universities (PID2020-119533GB-I00 and PDC2021-121716-I00), and the Spanish Association Against Cancer (AECC) (GCB15152955MÉND), the Worldwide Cancer Research Foundation(20-0284), World Cancer Research Fund International (2020_021), the BBVA Foundation (BBVABIOMED/18), La Caixa Foundation (LCF/PR/HR19/52160020), and the Fundacio Marato TV3 (201926-30-31). X.S. was supported by AGAUR (2017 SGR 324), MINECO (BIO2015-70092-R and PID2019-110198RB-I00), and the European Research Council (CONCERT, contract number 648201). CBMSO and IRB Barcelona are the recipients of a Severo Ochoa Award of Excellence from MINECO (Government of Spain)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

GATA6 identifies an immune-enriched phenotype linked to favorable outcomes in patients with pancreatic cancer undergoing upfront surgery

  • van Eijck, Casper W. F.
  • Real, Francisco X.
  • Malats i Riera, Núria
  • Vadgama, Disha
  • van den Bosch, Thierry P. P.
  • Doukas, Michail
  • van Eijck, Casper H. J.
  • Mustafa, Dana A. M.
  • Dutch Pancreatic Cancer Group (DPCG)
This study underscores GATA6's role in distinguishing classical and basal-like pancreatic ductal adenocarcinoma (PDAC) phenotypes. Retrospective studies associate GATA6 immunohistochemistry (IHC) expression with survival outcomes, warranting prospective validation. In a prospective treatment-naive cohort of patients with resected PDAC, GATA6 IHC proves a prognostic discriminator, associating high GATA6 expression with extended survival and the classical PDAC phenotype. However, GATA6's prognostic significance is numerically lower after gemcitabine-based neoadjuvant chemoradiotherapy compared to its significance in patients treated with upfront surgery. Furthermore, GATA6 is implicated in immunomodulation, although a comprehensive investigation of its immunological role is lacking. Treatment-naive PDAC tumors with varying GATA6 expression yield distinct immunological landscapes. Tumors highly expressing GATA6 show reduced infiltration of immunosuppressive regulatory T cells and M2 macrophages but increased infiltration of immune-stimulating, antigen-presenting, and activated T cells. Our findings caution against solely relying on GATA6 for molecular subtyping in clinical trials and open avenues for exploring immune-based combination therapies., The laboratory of C.H.J.v.E. receives financial support from the Survival with Pancreatic Cancer Foundation (www.supportcasper.nl) (grant number OVIT17-06). The laboratory of F.X.R. receives financial support from Ministerio de Ciencia, Innovación y Universidades (grant number PID2020-119533GB-I00). The CNIO receives support from the Ministerio de Ciencia, Innovación y Universidades as a Centro de Excelencia Severo Ochoa (grant number SEV-2015-0510).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

NFIC regulates ribosomal biology and ER stress in pancreatic acinar cells and restrains PDAC initiation

  • Cobo, Isidoro
  • Paliwal, Sumit
  • Bodas, Cristina
  • Felipe, Irene
  • Melià-Alomà, Júlia
  • Torres, Ariadna
  • Martínez-Villarreal, Jaime
  • Malumbres, Marina
  • García, Fernando
  • Millán, Irene
  • Del Pozo, Natalia
  • Park, Joo-Cheol
  • MacDonald, Ray J.
  • Muñoz, Javier
  • Méndez, Raúl
  • Real, Francisco X.
Pancreatic acinar cells rely on PTF1 and other transcription factors to deploy their transcriptional program. We identify NFIC as a NR5A2 interactor and regulator of acinar differentiation. NFIC binding sites are enriched in NR5A2 ChIP-Sequencing peaks. Nfic knockout mice have a smaller, histologically normal, pancreas with reduced acinar gene expression. NFIC binds and regulates the promoters of acinar genes and those involved in RNA/protein metabolism, and Nfic knockout pancreata show defective ribosomal RNA maturation. NFIC dampens the endoplasmic reticulum stress program through binding to gene promoters and is required for resolution of Tunicamycin-mediated stress. NFIC is down-regulated during caerulein pancreatitis and is required for recovery after damage. Normal human pancreata with low levels of NFIC transcripts display reduced expression of genes down-regulated in Nfic knockout mice. NFIC expression is down-regulated in mouse and human pancreatic ductal adenocarcinoma. Consistently, Nfic knockout mice develop a higher number of mutant Kras-driven pre-neoplastic lesions., This work was supported, in part, by grants SAF2011-29530, SAF2015-70553-R, RTI2018-101071-B-I00 from Ministerio de Ciencia, Innovación y Universidades (Madrid, Spain) (co-funded by the ERDF-EU) and RTICC from Instituto de Salud Carlos III (RD12/0036/0034) to FXR and grants PID2020-119533GB-I00, from Ministerio de Ciencia, Innovación y Universidades (Madrid, Spain), and GCB15152955MÉND, from the Spanish Association Against Cancer (AECC), to RM. I.C. was recipient of a Beca de Formación del Personal Investigador from Ministerio de Economía y Competitividad (Madrid, Spain). The research leading to these results has received funding from People Programme (Marie Curie Actions) of the European Union’s Seventh Framework Programme (FP7/2007-2013) (REA grant agreement n° 608765”). S.P. was supported by a Juan de la Cierva Programme fellowship from Ministerio de Ciencia, Innovación y Universidades. C.B. is supported by a FPI Fellowship from Ministerio de Ciencia, Innovación y Universidades. I.M. was supported by a Fellowship from Fundació Bancària La Caixa (ID 100010434) (grant number LCF/BQ/ES18/11670009). CNIO is supported by Ministerio de Ciencia, Innovación y Universidades as a Centro de Excelencia Severo Ochoa SEV-2015-0510.